Abstract
Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference65 articles.
1. GBD 2015 Mortality and Causes of Death Collaborators (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1459–1544.
2. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein;Ridker;N. Engl. J. Med.,2008
3. Anti-inflammatory drugs as promising cardiovascular treatments;Huet;Expert Rev. Cardiovasc. Ther.,2017
4. Coronary plaque disruption;Falk;Circulation,1995
5. Inflammation, atherosclerosis, and coronary artery disease;Hansson;N. Engl. J. Med.,2005
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献